{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-005467","form_type":"8-K","ticker":"VSBC","cik":"0001697884","company_name":"VITASPRING BIOMEDICAL CO. LTD.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.699820+00:00","generated_at":"2026-05-17T23:44:43.569120+00:00","sec_items":["5.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CEO and Chairman of VitaSpring face multiple Taiwan legal proceedings including indictments","bullets":["CEO Kao and Chairman Chu involved in criminal civil cases for unauthorized IP use, violations of Taiwan's Pharmaceutical Affairs Act.","Chu and Kao indicted March 31 2025 under Pharmaceutical Affairs Act; court hearings June 2 2025, next set for Sept 22 2025.","TMU fiduciary duty case ongoing; NT$500M (approx $15.5M) civil damages claim against Chu and others.","In exosome case, Chu acquitted by Tainan District Court; prosecutor has appealed.","Company says it is not a named party and does not expect material adverse effect on operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-005467","json":"https://secwatch.observer/filing/0001683168-25-005467.json","markdown":"https://secwatch.observer/filing/0001683168-25-005467.md","text":"https://secwatch.observer/filing/0001683168-25-005467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1697884/000168316825005467/0001683168-25-005467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1697884/000168316825005467/vitaspring_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:44:43.569120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}